OxyFile #338


CONTACT: Bill Roberts
         CTC, Inc.
         (513) 469-0202

For Immediate Release

New York City-- January 23, 1996 -- Medizone International, 
Inc. (OTC BB:MZEI.U) announced today that Richard Garrett 
Solomon (53) has been appointed to its Board of Directors by 
action of the Board.

His appointment increases the number of Directors to five.  
Dr. Joseph S. Latino, Ph D, Medizone International, Inc's 
Chief Executive Officer, stated that Mr. Solomon's 
appointment along with that of recent appointee, Ken Gropper, 
will serve to strenghthen Medizone's management team.

Mr. Solomon, a citizen of New Zealand, co-founded Havencare 
Hospitals, an elder care health facility, in 1978 and, until 
1996, occupied an executive position with that entity.  Mr. 
Solomon founded the New Zealand Council on Health Care 
Standards, on which he served as a member of the Council from 
1987 - 1995.  He also served as President of the New Zealand 
Private Hospitals Association from 1989 - 1993.

In 1995, Solwin Investments, an entity wholly owned by Mr. 
Solomon, entered into a joint venture with Medizone 
International, Inc. which resulted in the formation of 
Medizone's New Zealand subsidiary, Medizone New Zealand 
Limited, of which Mr. Solomon is a Director.

"Over the past three years I have had an increasing interest 
in Medizone International Inc. both as an investor and 
recently as a foreign joint venture partner.  Becoming a 
Director in 1996 is especially exciting to me as I believe 
the Company has achieved a number of breakthroughs which will 
assist us in the pursuit of commercial application of our 
patented technology and further advance acceptance of our 
process which uses a naturally occurring substance, Ozone, 
for the inactivation of certain viruses which are the basis 
of a number of today's major medical challenges," Mr. Solomon 

Medizone is developing Medizone (c), an ozone-based treatment
for diseases caused by lipid enveloped viruses, including
Acquired Immune Deficiency Syndrome (AIDS), Hepatitis B, and
Herpes; and is also developing its patented technology for
the decontamination of blood and blood products.

Medizone International, Inc. has a Front Page Web site at the
following new internet address: